Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American So...
November 01 2018 - 9:01AM
Nine abstracts accepted, including two oral
presentations
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in
developing novel, controllable cellular immunotherapies for cancers
and orphan inherited blood disorders, today reported
that eight abstracts–including two oral presentations–on the
Company’s lead product candidate rivo-cel (formerly BPX-501), in
addition to an abstract on its controllable CAR program, were
accepted for presentation at the 60th American Society of
Hematology (ASH) Annual Meeting.
Among the highlights will be late interim analyses from the
BP-004 trial in children with acute leukemias and nonmalignant
blood diseases, as well as the comparator C-004 trial—a
multicenter, observational study of similar pediatric patients
receiving a matched unrelated donor (MUD) transplant. As part of
these interim analyses, the presentations will include the first
reports of transplant Event-Free Survival at 180 days, the primary
endpoint of the studies that will serve as the basis for MAA filing
in Europe. In addition, longer term follow-up of disease outcomes
from several patient subsets, including ALL, AML, thalassemia
major, and Fanconi anemia, will be presented. Finally, the
cumulative clinical experience of patients in BP-004 who received
rimiducid to treat steroid refractory Graft-versus-Host-Disease
will also be presented. ASH 2018 is being held in San Diego,
California on December 1-4.
RIVO-CEL PRESENTATION DETAILS
Poster Presentation: “Administration of BPX-501
Cells Following αβ T and B-Cell-Depleted HLA-Haploidentical HSCT
(haplo-HSCT) in Children with Malignant or Non-Malignant
Disorders”Abstract Number: 2171Session
Name: 732. Clinical Allogeneic Transplantation: Results:
Poster I Session Date: Saturday, December 1, 2018
Presentation Time: 6:15 p.m. – 8:15 p.m. PT
Oral Presentation: “Administration of BPX-501
Cells Following αβ T and B-Cell-Depleted HLA Haploidentical HSCT
(haplo-HSCT) in Children with Acute Leukemias”Abstract
Number: 307Session Name: 732. Clinical
Allogeneic Transplantation: Results: Optimizing Outcomes After
Allogeneic Transplantation Session Date:
Sunday, December 2, 2018 Session Time: 7:30 a.m. -
9:00 a.m. PTPresentation Time: 7:30 a.m. PT
Oral Presentation: “Administration of BPX-501
Following αβ T and B-cell Depleted Haplo-HSCT in Children with
Transfusion-Dependent Thalassemia”Abstract Number:
166Session Name: 112. Thalassemia and Globin Gene
Regulation: ClinicalSession Date: Saturday,
December 1, 2018Session Time: 2:00 p.m. - 3:30
p.m. PTPresentation Time: 2:45 p.m. PT
Poster Presentation: “Administration of
Rimiducid Following Haploidentical BPX-501 Cells in Children with
Malignant or Non-Malignant Disorders Who Develop
Graft-versus-Host-Disease (GvHD)”Abstract
Number: 2207Session Name: 801. Gene
Therapy and Transfer: Poster I Session Date:
Saturday, December 1, 2018Presentation Time: 6:15
p.m. - 8:15 p.m. PT
Poster Presentation: “Characterization of
Allogeneic T Cells Expressing Inducible Caspase-9 Following
Adoptive Transfer in Children Receiving an HLA-Haploidentical
Hematopoietic Stem Cell Transplant for the Treatment of Myeloid
Malignancies”Abstract Number: 4534Session
Name: 703. Adoptive Immunotherapy: Poster
III Session Date: Monday, December 3,
2018 Presentation Time: 6:00 p.m. - 8:00 p.m.
PT
Poster Presentation: “Differential Expression
of Inducible Caspase-9 (iC9) in Allogeneic T cells Allows Selective
Depletion of Activated T Cells Following Exposure to Rimiducid and
Permits In Vivo Allodepletion”Abstract Number:
3496 Session Name: 801. Gene Therapy and
Transfer: Poster II Session Date: Sunday,
December 2, 2018Presentation Time: 6:00 p.m. -
8:00 p.m. PT
Poster Presentation: “Administration of BPX-501
Cells Following αβ T and B-Cell-Depleted HLA-Haploidentical HSCT in
Children with Fanconi Anemia”Abstract Number:
4654Session Name: 732. Clinical Allogeneic
Transplantation: Results: Poster IIISession Date:
Monday, December 3, 2018 Presentation Time: 6:00
p.m. - 8:00 p.m. PT
Poster Presentation: “A Simplified Method for
Transduction and Expansion of T Cells for Clinical
Application”Abstract Number:
4555 Session Name: 711. Cell Collection and
Processing: Poster III Session Date: Monday,
December 3, 2018 Presentation Time: 6:00
p.m. - 8:00 p.m. PT
CONTROLLABLE CAR PRESENTATION DETAILS
Poster Presentation: “Regulated Natural Killer
Cell Expansion and Anti-Tumor Activity with Inducible
MyD88/CD40”Abstract Number: 4550Session
Name: 703. Adoptive Immunotherapy: Poster III
Session Date: Monday, December 3, 2018
Presentation Time: 6:00 p.m. - 8:00 p.m.
PT
About Bellicum Pharmaceuticals Bellicum is
a clinical stage biopharmaceutical company striving to deliver
cures through controllable cell therapies. The Company’s
next-generation product candidates are differentiated by powerful
cell signaling technologies designed to produce more effective
CAR-T, TCR and allogeneic T cell therapies. Its lead product
candidate, rivo-cel, is an allogeneic polyclonal T cell product
that has shown promising results in reducing leukemia relapse after
a stem cell transplant. Bellicum’s lead GoCAR-T candidate, BPX-601,
is designed to be a more efficacious CAR-T cell product capable of
overriding key immune inhibitory mechanisms. More information can
be found at www.bellicum.com.
Source: Bellicum Pharmaceuticals
Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com
Media:
Solebury Trout
Brad Miles
646-513-3125
bmiles@soleburytrout.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2023 to Apr 2024